Log inSign up
AAOIFI No. 21 screening

Is ASND halal?

Ascendis Pharma A/S

Halal

Ascendis Pharma A/S passed every check under AAOIFI Shariah standard No. 21: no prohibited business activity, and all three financial ratios are within limits.

Checked: 15 October 2026

Exchange

NASDAQ

Price

225.25

Day

-0.60%

Market cap

$14.94B

Industry

Biotechnology

Sector

Healthcare

What the company does

Ascendis Pharma (Denmark) is a biotech selling Skytrofa (weekly growth hormone for children) and Yorvipath (hypoparathyroidism), built on its TransCon technology. Its money comes from prescription-drug sales.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $504.62M ÷ 36-month average market cap $10.69B = 4.7%

    4.7%

    Pass

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $910.71M ÷ 36-month average market cap $10.69B = 8.5%

    8.5%

    Pass

  • Non-compliant income / total revenue

    limit 5%

    Interest income $17.16M ÷ annual revenue $807.41M (2025) = 2.1%

    2.1%

    Pass

Figures from the company's filings (2026-06-30), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict. Today's market cap: $14.94B.

For information (AAOIFI 3/1 note): cash + receivables are 45.3% of total assets (2026-06-30). AAOIFI recommends tangible assets of at least one third — this figure does not affect the verdict, and other major screeners do not apply it either.

In the lists

In the S&P 500
Not in the S&P 500
Among halal stocks
0.02% · #333 of 1454

Halal stocks in the same industry

The largest halal stocks in Biotechnology — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.

Earnings historyASND's next report date, EPS estimate vs actual for recent quarters and the post-earnings price move.View earnings →